Precigen is a biopharmaceutical company that develops gene medicines for patients with cancer, autoimmune and infectious diseases. PGEN reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 25 | B. Riley Securities | Initiated | Buy | |
| Aug 5 | HC Wainwright & Co. | Target raised | Buy | |
| May 28 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How PGEN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.
Whale Options Flow
90DNo whale options trades in PGEN in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PGEN is in one of them and how their past PGEN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PGEN in an article yet. Here's the latest on the wider market.
About Precigen
Precigen is a biopharmaceutical company based in Germantown, Maryland, that develops medicines for patients with hard to treat diseases. Its main focus areas are cancer, autoimmune disorders and infectious diseases. Its approved product, Papzimeos, is an immunotherapy for adults with recurrent respiratory papillomatosis, a rare disease caused by HPV infection. The company also develops cell and gene therapies that are in clinical trials or at earlier research stages.
- Headquarters
- Germantown, MD
- Founded
- 1998
- Website
- precigen.com ↗